215 related articles for article (PubMed ID: 34163463)
1. Absence of Non-Canonical, Inhibitory
Cardona Gloria Y; Bernhart SH; Fillinger S; Wolz OO; Dickhöfer S; Admard J; Ossowski S; Nahnsen S; Siebert R; Weber ANR
Front Immunol; 2021; 12():616451. PubMed ID: 34163463
[TBL] [Abstract][Full Text] [Related]
2. NF-κB mediates lipopolysaccharide-induced alternative pre-mRNA splicing of
Lee FF; Davidson K; Harris C; McClendon J; Janssen WJ; Alper S
J Biol Chem; 2020 May; 295(18):6236-6248. PubMed ID: 32179652
[TBL] [Abstract][Full Text] [Related]
3. Oncogenically active MYD88 mutations in human lymphoma.
Ngo VN; Young RM; Schmitz R; Jhavar S; Xiao W; Lim KH; Kohlhammer H; Xu W; Yang Y; Zhao H; Shaffer AL; Romesser P; Wright G; Powell J; Rosenwald A; Muller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Staudt LM
Nature; 2011 Feb; 470(7332):115-9. PubMed ID: 21179087
[TBL] [Abstract][Full Text] [Related]
4. MyD88S, a splice variant of MyD88, differentially modulates NF-kappaB- and AP-1-dependent gene expression.
Janssens S; Burns K; Vercammen E; Tschopp J; Beyaert R
FEBS Lett; 2003 Jul; 548(1-3):103-7. PubMed ID: 12885415
[TBL] [Abstract][Full Text] [Related]
5. Transcriptome Analysis of Diffuse Large B-Cell Lymphoma Cells Inducibly Expressing MyD88 L265P Mutation Identifies Upregulated CD44, LGALS3, NFKBIZ, and BATF as Downstream Targets of Oncogenic NF-κB Signaling.
Turi M; Anilkumar Sithara A; Hofmanová L; Žihala D; Radhakrishnan D; Vdovin A; Knápková S; Ševčíková T; Chyra Z; Jelínek T; Šimíček M; Gullà A; Anderson KC; Hájek R; Hrdinka M
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982699
[TBL] [Abstract][Full Text] [Related]
6. MYD88 L265P elicits mutation-specific ubiquitination to drive NF-κB activation and lymphomagenesis.
Yu X; Li W; Deng Q; Liu H; Wang X; Hu H; Cao Y; Xu-Monette ZY; Li L; Zhang M; Lu Z; Young KH; Li Y
Blood; 2021 Mar; 137(12):1615-1627. PubMed ID: 33025009
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4.
Burns K; Janssens S; Brissoni B; Olivos N; Beyaert R; Tschopp J
J Exp Med; 2003 Jan; 197(2):263-8. PubMed ID: 12538665
[TBL] [Abstract][Full Text] [Related]
8. The oncogenic human B-cell lymphoma MYD88 L265P mutation genocopies activation by phosphorylation at the Toll/interleukin-1 receptor (TIR) domain.
Minderman M; Lantermans H; van der Zwaan C; Hoogendijk AJ; van den Biggelaar M; Kersten MJ; Spaargaren M; Pals ST
Blood Cancer J; 2023 Aug; 13(1):125. PubMed ID: 37591861
[TBL] [Abstract][Full Text] [Related]
9. NF-κB activation via MyD88-dependent Toll-like receptor signaling is inhibited by trichothecene mycotoxin deoxynivalenol.
Sugiyama K; Muroi M; Kinoshita M; Hamada O; Minai Y; Sugita-Konishi Y; Kamata Y; Tanamoto K
J Toxicol Sci; 2016 Apr; 41(2):273-9. PubMed ID: 26961612
[TBL] [Abstract][Full Text] [Related]
10. Regulation of interleukin-1- and lipopolysaccharide-induced NF-kappaB activation by alternative splicing of MyD88.
Janssens S; Burns K; Tschopp J; Beyaert R
Curr Biol; 2002 Mar; 12(6):467-71. PubMed ID: 11909531
[TBL] [Abstract][Full Text] [Related]
11. HSP110 sustains chronic NF-κB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization.
Boudesco C; Verhoeyen E; Martin L; Chassagne-Clement C; Salmi L; Mhaidly R; Pangault C; Fest T; Ramla S; Jardin F; Wolz OO; Weber ANR; Garrido C; Jego G
Blood; 2018 Aug; 132(5):510-520. PubMed ID: 29871863
[TBL] [Abstract][Full Text] [Related]
12. MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma.
Aggarwal V; Das A; Bal A; Srinivasan R; Das R; Prakash G; Malhotra P; Varma S
Appl Immunohistochem Mol Morphol; 2019 Apr; 27(4):311-318. PubMed ID: 29734251
[TBL] [Abstract][Full Text] [Related]
13. Increased LIGHT expression and activation of non-canonical NF-κB are observed in gastric lesions of MyD88-deficient mice upon Helicobacter felis infection.
Mejías-Luque R; Lozano-Pope I; Wanisch A; Heikenwälder M; Gerhard M; Obonyo M
Sci Rep; 2019 May; 9(1):7030. PubMed ID: 31065023
[TBL] [Abstract][Full Text] [Related]
14. A multiprotein supercomplex controlling oncogenic signalling in lymphoma.
Phelan JD; Young RM; Webster DE; Roulland S; Wright GW; Kasbekar M; Shaffer AL; Ceribelli M; Wang JQ; Schmitz R; Nakagawa M; Bachy E; Huang DW; Ji Y; Chen L; Yang Y; Zhao H; Yu X; Xu W; Palisoc MM; Valadez RR; Davies-Hill T; Wilson WH; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza LM; Rodriguez FJ; Estephan F; Holdhoff M; Kruhlak MJ; Hewitt SM; Thomas CJ; Pittaluga S; Oellerich T; Staudt LM
Nature; 2018 Aug; 560(7718):387-391. PubMed ID: 29925955
[TBL] [Abstract][Full Text] [Related]
15. Vinculin B inhibits NF-κB signaling pathway by targeting MyD88 in miiuy croaker, Miichthys miiuy.
Cao B; Zhao Y; Luo Q; Chen Y; Xu T; Sun Y
Fish Shellfish Immunol; 2023 Apr; 135():108683. PubMed ID: 36931481
[TBL] [Abstract][Full Text] [Related]
16. CRL3-SPOP ubiquitin ligase complex suppresses the growth of diffuse large B-cell lymphoma by negatively regulating the MyD88/NF-κB signaling.
Jin X; Shi Q; Li Q; Zhou L; Wang J; Jiang L; Zhao X; Feng K; Lin T; Lin Z; Zhuang H; Yang J; Hu C; Zhang L; Shen L; Lu Y; Zhu J; Wang H; Qi H; Meng X; Xi Y; Pan J; Fang S; Tian H; Zhou C; Zhang P; Gao K; Zhao SM; Li Y; Gong Z; Wang C
Leukemia; 2020 May; 34(5):1305-1314. PubMed ID: 31776466
[TBL] [Abstract][Full Text] [Related]
17. Molecular identification and functional analysis of two variants of myeloid differentiation factor 88 (MyD88) from disk abalone (Haliotis discus discus).
Priyathilaka TT; Bathige SDNK; Lee S; Lee J
Dev Comp Immunol; 2018 Feb; 79():113-127. PubMed ID: 29074103
[TBL] [Abstract][Full Text] [Related]
18. Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas.
Liu X; Chen JG; Munshi M; Hunter ZR; Xu L; Kofides A; Tsakmaklis N; Demos MG; Guerrera ML; Chan GG; Jimenez C; Patterson CJ; Meid K; Keezer A; Castillo JJ; Treon SP; Yang G
Blood Adv; 2020 Jan; 4(1):141-153. PubMed ID: 31935288
[TBL] [Abstract][Full Text] [Related]
19. MyD88-mediated signaling intercedes in neurogenic muscle atrophy through multiple mechanisms.
Parveen A; Bohnert KR; Tomaz da Silva M; Wen Y; Bhat R; Roy A; Kumar A
FASEB J; 2021 Aug; 35(8):e21821. PubMed ID: 34325487
[TBL] [Abstract][Full Text] [Related]
20. Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas.
Reimann M; Schrezenmeier J; Richter-Pechanska P; Dolnik A; Hick TP; Schleich K; Cai X; Fan DNY; Lohneis P; Maßwig S; Denker S; Busse A; Knittel G; Flümann R; Childs D; Childs L; Gätjens-Sanchez AM; Bullinger L; Rosenwald A; Reinhardt HC; Schmitt CA
Blood; 2021 May; 137(20):2785-2799. PubMed ID: 33232972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
